Expertise in
9
conditions

Dr. Mark S. Kipnes

Endocrinology
Diabetes And Glandular Disease Clinic PA
5107 Medical Dr, 
San Antonio, TX 
Accepting New Patients
Referral required
Before you request
Expertise in
9
conditions
Diabetes And Glandular Disease Clinic PA
5107 Medical Dr, 
San Antonio, TX 

Overview

Mark Kipnes is an Endocrinologist practicing medicine in San Antonio, Texas.

Dr. Kipnes is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Type 2 Diabetes (T2D), Type 1 Diabetes (T1D), Low Blood Sugar, and Diabetic Neuropathy.

He is actively involved in clinical research, co-authoring 30 peer reviewed articles and participating in 11 clinical trials. Dr. Kipnes is currently accepting new patients.

Specialties

Endocrinology

Licenses

Internal Medicine in TX

Languages Spoken

English
French
German
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community First Health Plans
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Diabetes and Glandular Disease Clinic PA
5107 Medical Dr, San Antonio, TX 78229

Additional Areas of Focus

Dr. Kipnes has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children With Idiopathic Growth Hormone Deficiency (GHD)
A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children With Idiopathic Growth Hormone Deficiency (GHD)
Enrollment Status: Completed
Publish Date: June 17, 2026
Intervention Type: Drug
Study Drugs: LUM-201, rhGH Norditropin® pen
Study Phase: Phase 2
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of TOL-3021 in Patients With New Onset or Established Type 1 Diabetes Mellitus
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of TOL-3021 in Patients With New Onset or Established Type 1 Diabetes Mellitus
Enrollment Status: Terminated
Publish Date: May 20, 2026
Intervention Type: Other, Biological
Study Drug: TOL-3021
Study Phase: Phase 2
Multi-center, Randomized, Parallel, Adaptive, Controlled Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control (CSII, MDI and SAP) at Home
Multi-center, Randomized, Parallel, Adaptive, Controlled Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control (CSII, MDI and SAP) at Home
Enrollment Status: Completed
Publish Date: August 19, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Post- Approval Study to Evaluate the Long-term Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System
A Post- Approval Study to Evaluate the Long-term Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System
Enrollment Status: Completed
Publish Date: June 12, 2025
Intervention Type: Device
Study Phase: Not Applicable
INHALE-1: A 26-week Primary Treatment Phase, With 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza® Versus Rapid-acting Insulin Analog Injections, Both in Combination With a Basal Insulin, in Pediatric Subjects With Type 1 or Type 2 Diabetes Mellitus
INHALE-1: A 26-week Primary Treatment Phase, With 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza® Versus Rapid-acting Insulin Analog Injections, Both in Combination With a Basal Insulin, in Pediatric Subjects With Type 1 or Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: May 06, 2025
Intervention Type: Biological
Study Drugs: Afrezza, Rapid-acting Insulin Analog, Basal Insulin
Study Phase: Phase 3
Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects
Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Device
Study Phase: Not Applicable
Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes
Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: January 24, 2022
Intervention Type: Drug
Study Drugs: LY900014, Insulin Lispro
Study Phase: Phase 3
Prediabetes and Type 2 Diabetes Data Collection Study: T2Help
Prediabetes and Type 2 Diabetes Data Collection Study: T2Help
Enrollment Status: Unknown
Publish Date: October 05, 2021
Intervention Type: Device
Continuous Glucose Monitoring & Management In Type 2 Diabetes
Continuous Glucose Monitoring & Management In Type 2 Diabetes
Enrollment Status: Completed
Publish Date: March 22, 2021
Intervention Type: Device
Study Phase: Not Applicable
View 9 Less Clinical Trials

30 Total Publications

Safety and Effectiveness of MiniMed™ 780G Advanced Hybrid Closed-Loop Use with Ultrarapid Insulin Lispro-AABC in Pediatric and Adult Type 1 Diabetes.
Safety and Effectiveness of MiniMed™ 780G Advanced Hybrid Closed-Loop Use with Ultrarapid Insulin Lispro-AABC in Pediatric and Adult Type 1 Diabetes.
Journal: Diabetes technology & therapeutics
Published: April 29, 2026
Similar Doctors
Expertise in
4
conditions
Dr. Marzieh S. Salehi
Endocrinology
Expertise in
4
conditions
Dr. Marzieh S. Salehi
Endocrinology
Referral required
Before you request

University Of Texas Health Science Center San Antonio

7703 Floyd Curl Dr, 
San Antonio, TX 
 (0.7 miles away)
210-450-9050
Languages Spoken:
English, Farsi
See accepted insurances
Accepting New Patients

Marzieh Salehi is an Endocrinologist practicing medicine in San Antonio, Texas. Dr. Salehi is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Low Blood Sugar, Obesity, Type 2 Diabetes (T2D), Gastric Bypass, and Sleeve Gastrectomy. Dr. Salehi is currently accepting new patients.

Expertise in
51
conditions
Dr. Shahid A. Aziz
Endocrinology
Expertise in
51
conditions
Dr. Shahid A. Aziz
Endocrinology
Referral required
Before you request

Office

10818 Town Center Dr Ste 101, 
San Antonio, TX 
 (6.4 miles away)
210-352-5006
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Shahid Aziz is an Endocrinologist practicing medicine in San Antonio, Texas. Dr. Aziz is highly rated in 51 conditions, according to our data. His clinical expertise encompasses Type 2 Diabetes (T2D), Hypothyroidism, Obesity in Children, and Type 1 Diabetes (T1D). Dr. Aziz is currently accepting new patients.

Expertise in
29
conditions
Dr. Jaime O. Cruz
Endocrinology
Expertise in
29
conditions
Dr. Jaime O. Cruz
Endocrinology
Referral required
Before you request

San Antonio Diabetes And Endocrinology Consultants PLLC

155 E Sonterra Blvd Ste 105, 
San Antonio, TX 
 (10.0 miles away)
210-314-8045
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Jaime Cruz is an Endocrinologist practicing medicine in San Antonio, Texas. Dr. Cruz is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Hashimoto Thyroiditis, Graves Disease, Thyroid Storm, and Obesity in Children. Dr. Cruz is currently accepting new patients.

Frequently Asked Questions about Dr. Mark S. Kipnes

How do I make an appointment with Dr. Mark S. Kipnes?

You can book an appointment with Dr. Mark S. Kipnes by calling their office at 210-614-8612. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mark S. Kipnes a top-rated expert for Type 2 Diabetes (T2D)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark S. Kipnes is classified as an Distinguished expert for Type 2 Diabetes (T2D), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark S. Kipnes specialize in?

While Dr. Mark S. Kipnes is a Endocrinology, they have specific expertise in Type 2 Diabetes (T2D), Type 1 Diabetes (T1D), and Low Blood Sugar. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Endocrinology.

Does Dr. Mark S. Kipnes participate in research or clinical trials?

Yes. Dr. Mark S. Kipnes has published 30 articles and abstracts on conditions like Type 2 Diabetes (T2D). You can view a list of Dr. Mark S. Kipnes's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mark S. Kipnes accept my insurance?

Dr. Mark S. Kipnes accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 210-614-8612 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kipnes's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 23 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile